Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children's Oncology Group.
Shastri VM, Chauhan L, Gbadamosi M, Alonzo TA, Wang YC, Aplenc R, Hirsch BA, Kolb EA, Gamis AS, Meshinchi S, Lamba JK. Shastri VM, et al. Among authors: gbadamosi m. Clin Cancer Res. 2024 Jan 10:10.1158/1078-0432.CCR-23-2073. doi: 10.1158/1078-0432.CCR-23-2073. Online ahead of print. Clin Cancer Res. 2024. PMID: 38197878
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
Gbadamosi MO, Shastri VM, Elsayed AH, Ries R, Olabige O, Nguyen NHK, De Jesus A, Wang YC, Dang A, Hirsch BA, Alonzo TA, Gamis A, Meshinchi S, Lamba JK. Gbadamosi MO, et al. Leukemia. 2022 Aug;36(8):2022-2031. doi: 10.1038/s41375-022-01622-0. Epub 2022 Jun 10. Leukemia. 2022. PMID: 35688939 Free PMC article.
CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents.
Papageorgiou I, Loken MR, Brodersen LE, Gbadamosi M, Uy GL, Meshinchi S, Lamba JK. Papageorgiou I, et al. Among authors: gbadamosi m. Leuk Lymphoma. 2019 Sep;60(9):2287-2290. doi: 10.1080/10428194.2019.1569232. Epub 2019 Feb 5. Leuk Lymphoma. 2019. PMID: 30721105 Free PMC article. No abstract available.
Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML.
Nguyen NHK, Rafiee R, Tagmount A, Sobh A, Loguinov A, de Jesus Sosa AK, Elsayed AH, Gbadamosi M, Seligson N, Cogle CR, Rubnitz J, Ribeiro R, Downing J, Cao X, Pounds SB, Vulpe CD, Lamba JK. Nguyen NHK, et al. Among authors: gbadamosi m. Blood Adv. 2023 May 9;7(9):1769-1783. doi: 10.1182/bloodadvances.2022007934. Blood Adv. 2023. PMID: 36111891 Free PMC article.
Accessibility and TB patient satisfaction in Nigeria.
Alatise MA, Narasimhan P, Gbadamosi MD, Chughtai AA. Alatise MA, et al. Among authors: gbadamosi md. Int J Tuberc Lung Dis. 2024 Dec 1;28(12):585-591. doi: 10.5588/ijtld.24.0314. Int J Tuberc Lung Dis. 2024. PMID: 39578359
QSAR, molecular docking, MD simulations, and ADMET screening identify potential Heliotropium indicum leads against key targets in benign prostatic hyperplasia.
Omirin ES, Aribisala PO, Olugbogi EA, Adeniran OY, Emaleku SA, Saliu JA, Fapohunda O, Omirin AK, Gbadamosi MO, Wopara I. Omirin ES, et al. Among authors: gbadamosi mo. In Silico Pharmacol. 2024 Nov 19;12(2):107. doi: 10.1007/s40203-024-00280-7. eCollection 2024. In Silico Pharmacol. 2024. PMID: 39569034
Challenges of Screening and Investigations of Contacts of Patients with Tuberculosis in Oyo and Osun States, Nigeria.
Agbaje A, Dakum P, Daniel O, Chukwuma A, Chijoke-Akaniro O, Okpokoro E, Akingbesote S, Anyomi C, Adekunle A, Alege A, Gbadamosi M, Babalola O, Mensah C, Eneogu R, Ihesie A, Adelekan A. Agbaje A, et al. Among authors: gbadamosi m. Trop Med Infect Dis. 2024 Jun 28;9(7):144. doi: 10.3390/tropicalmed9070144. Trop Med Infect Dis. 2024. PMID: 39058186 Free PMC article.
25 results